11 results
6-K
EX-99.1
IPHA
Innate Pharma
21 Mar 24
Summary of Consolidated Financial Statements and Notes
9:20am
) Antitrust Improvements Act of 1976 and the effectiveness of the licensing agreement as of January 24, 2023. Consequently, the Company received an upfront
6-K
EX-99.1
IPHA
Innate Pharma
21 Mar 24
Innate Pharma reports Full Year 2023 Financial Results and Business Update
6:01am
) Antitrust Improvements Act of 1976 and the effectiveness of the licensing agreement as of January 24, 2023. Consequently, the Company received an upfront
6-K
EX-99.1
IPHA
Innate Pharma
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and the effectiveness of the licensing agreement as of January 24, 2023 … . On January 25, 2023, the Company announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976
6-K
EX-99.2
IPHA
Innate Pharma
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and the effectiveness of the licensing agreement … the Hart-Scott-Rodino Antitrust Improvements Act with respect to the expansion of its collaboration with Sanofi. As a reminder, On December 19, 2022
6-K
EX-99.1
ovwcfzr 9gafmtjx8161
14 Sep 23
Innate Pharma S.a. 6-K
6:00am
20-F/A
EX-4.9
0xvl7 v71rzf
20 Apr 23
Annual report (foreign) (amended)
8:47am
F-1
EX-10.3
fevj9a61he2uac7rt
20 Sep 19
Registration statement (foreign)
4:08pm
F-1
EX-10.1
dclfzoa4v 9odk5y
20 Sep 19
Registration statement (foreign)
4:08pm
DRS/A
EX-10.1
ckmnt
30 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
EX-10.3
k343qm272qb5 uts390
30 Aug 19
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next